Dublin, March 28, 2017 -- Research and Markets has announced the addition of the "Global Psoriasis Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By Route of Administration (Systemic, Topical), By Mechanism of Action (TNF Inhibitors, Interleukin Blockers) Outlook 2022" report to their offering.
According to World Health Organization, the prevalence of psoriasis in different countries ranges between 0.09% and 11.4%. Treatment of this disease is based on controlling of its symptoms. Topical and systemic therapy drugs are used in combination, in order to combat this disease.
As per the report Global Psoriasis Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By Route of Administration (Systemic, Topical), By Mechanism of Action (TNF Inhibitors, Interleukin Blockers) Outlook 2022, the global psoriasis drugs market is anticipated to witness a high growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global psoriasis drugs market. The report provides insight about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities available for growth of the global psoriasis drugs market.
The global psoriasis drugs market has been segmented on the basis of type of drug molecule into biologics drugs and small molecule/chemical drugs. Biologics are gaining popularity due to the high efficacy and specificity of these drugs for the treatment of various types of psoriasis. Moreover, the increasing awareness about these drugs among people is also helping its market to grow all across the globe.
Furthermore, the global psoriasis drugs market has also been segmented on the basis of their route of administration. According to the report, the psoriasis drugs can be administered by topical route as well as systemic route. Systemic route of administration is expected to witness a high growth owing to its high efficacy. Similarly, the market has been segmented on the basis of mechanism of action of the drug into TNF inhibitors, interleukin blockers, and others. Interleukin blockers are gaining high popularity amongst all classes of drugs.
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Psoriasis: An Overview
4. Market Dynamics
4.1 Drivers
4.1.1 Rising Prevalence of Psoriasis
4.1.2 Increasing Awareness
4.1.3 Growing Geriatric Population
4.1.4 Rising Healthcare Expenditure
4.2 Challenges
4.2.1 Patent Cliff of Blockbuster Drugs
4.2.2 High Cost
4.3 Opportunities
4.3.1 Biologic Drugs Flaring Up Psoriasis Drugs Market
4.3.2 Incessant Launch of Novel Products
5. Global Psoriasis Drugs Market Outlook 2022
6. Market Segmentation by Type of Drug Molecule
6.1 Biologic Drugs
6.2 Small Molecule/Chemical Drugs
7. Market Segmentation by Route of Administration
7.1 Systemic
7.2 Topical
8. Market Segmentation by Mechanism of Action
8.1 TNF Inhibitors
8.2 Interleukin Blockers
8.3 Others
9. Market Segmentation by Geography
9.1 North America
9.2 Europe
9.3 Asia-Pacific
10. Trends & Developments
10.1 Interleukin Inhibitors Driving Psoriasis Drugs Market
10.2 TNF-alpha Blockers for the Treatment of Psoriasis
11. Mergers, Acquisitions & Collaborations
12. Pipeline Analysis
13. Porter's Five Forces Analysis
14. Key Players
14.1 AbbVie Inc.
14.2 Biocon
14.3 Pfizer Inc.
14.4 Novartis
14.5 Eli Lilly and Company
14.6 Celltrion Inc.
14.7 Celgene Corporation
14.8 Johnson & Johnson
14.9 Dr.Reddy's Laboratories
14.10 Amgen Inc.
For more information about this report visit http://www.researchandmarkets.com/research/d3d8zn/global_psoriasis
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Immune Disorders Drugs, Psoriasis Drugs


UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests
Starlink Internet Remains Active in Iran Despite Nationwide Blackout
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 



